PMID: 971012Oct 1, 1976

Staphylococcal sepsis in patients on chronic hemodialysis regimens: intravenous treatment with vancomycin given once weekly

Archives of Internal Medicine
C G BarcenasM G White

Abstract

Five patients on chronic hemodialysis regimens were hospitalized with six episodes of Staphylococcus aureus septicemia. Three of the patents acquired the infection during home dialysis, and it was related to the hemodialysis circulatory-access site in four. Initial therapy was methicillin sodium. Vanomycin hydrochloride was given in a 1-gm, single, weekly dose as the sole antibiotic after a short interval (mean, three days). Five of the six episodes were treated successfully. Staphylococcus epidermidis grew in blood cultures obtained during one of the treatments. The advantages of this regimen included a more prompt ambulation and the discontuation of constant infusions in patients with no peripheral veins available.

Citations

Jan 1, 1989·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·R SchoumacherD A Spyker
Nov 13, 2004·Current Infectious Disease Reports·Philip M Polgreen, L A Herwaldt
Apr 1, 1977·The American Journal of Medicine·J S Cheigh
Jun 1, 1997·International Journal of Antimicrobial Agents·F J Schmitz, M E Jones
Jan 1, 1977·Journal of Dialysis·D L LatosR H Alford
Sep 1, 1996·Kidney International·R H Barth, N DeVincenzo
Oct 20, 1998·The Journal of Hospital Infection·L A Herwaldt

Related Concepts

Blood Bactericidal Activity
Drug Administration Schedule
Hemodialysis
Parenteral Infusion
Kidney Failure, Chronic
Penicillin Resistance
Staphylococcal Infections
Staphylococcus aureus
AB-Vancomycin
Pyemia

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.